{"id":"lopinavir-ritonavir-soft-gel-capsule","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Lopinavir is a protease inhibitor that binds to the protease enzyme, preventing it from cleaving viral proteins. Ritonavir is a protease inhibitor that also inhibits the CYP3A4 enzyme, increasing the levels of lopinavir in the body.","oneSentence":"Lopinavir/ritonavir is a combination of two antiretroviral drugs that inhibit the protease enzyme in HIV, preventing viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:24.156Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of HIV-1 infection in adults and children"}]},"trialDetails":[{"nctId":"NCT00720590","phase":"NA","title":"Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors","status":"COMPLETED","sponsor":"Indiana University","startDate":"2003-11","conditions":"Endothelial Dysfunction","enrollment":30},{"nctId":"NCT00414518","phase":"NA","title":"Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2007-01","conditions":"HIV Infections","enrollment":16},{"nctId":"NCT00262522","phase":"PHASE3","title":"Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects","status":"COMPLETED","sponsor":"Abbott","startDate":"2005-11","conditions":"Human Immunodeficiency Virus Infections","enrollment":664},{"nctId":"NCT01002898","phase":"PHASE3","title":"Ritonavir-boosted Lopinavir Monotherapy","status":"COMPLETED","sponsor":"Bamrasnaradura Infectious Diseases Institute","startDate":"2007-04","conditions":"HIV","enrollment":40},{"nctId":"NCT00268827","phase":"PHASE4","title":"A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort","status":"COMPLETED","sponsor":"AIDS Arms Inc.","startDate":"2005-12","conditions":"HIV-1, AIDS","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Kaletra"],"phase":"phase_3","status":"active","brandName":"lopinavir/ritonavir soft gel capsule","genericName":"lopinavir/ritonavir soft gel capsule","companyName":"Bamrasnaradura Infectious Diseases Institute","companyId":"bamrasnaradura-infectious-diseases-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lopinavir/ritonavir is a combination of two antiretroviral drugs that inhibit the protease enzyme in HIV, preventing viral replication. Used for Treatment of HIV-1 infection in adults and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}